Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome
暂无分享,去创建一个
L. Wilson | K. Roberts | B. Kann | S. Aneja | Henry S. Park | D. Yeboa | M. Girardi | F. Foss
[1] N. Shah,et al. Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Cerhan,et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.
[3] R. Bindra,et al. Adjuvant chemotherapy and overall survival in adult medulloblastoma , 2016, Neuro-oncology.
[4] L. Wilson,et al. Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] S. Hung,et al. Higher caseload improves cervical cancer survival in patients treated with brachytherapy , 2014, Radiation oncology.
[6] L. Wilson,et al. Poorer prognosis of African-American patients with mycosis fungoides: an analysis of the SEER dataset, 1988 to 2008. , 2014, Clinical lymphoma, myeloma & leukemia.
[7] M. Beyer,et al. Systematic review of combination therapies for mycosis fungoides. , 2014, Cancer treatment reviews.
[8] M. Krasnik,et al. High procedure volume is strongly associated with improved survival after lung cancer surgery. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] L. Holmberg,et al. Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004–2008 , 2012, Gut.
[10] E. Ward,et al. Insurance status and racial differences in uterine cancer survival: a study of patients in the National Cancer Database. , 2011, Gynecologic oncology.
[11] J. Scarisbrick,et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Amy Y. Chen,et al. Improved survival is associated with treatment at high‐volume teaching facilities for patients with advanced stage laryngeal cancer , 2010, Cancer.
[13] Nicola Pimpinelli,et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects , 2005, Journal of cutaneous pathology.
[14] M. Gonen,et al. Long-Term Survival Is Superior After Resection for Cancer in High-Volume Centers , 2005, Annals of surgery.
[15] S. Mehta,et al. Role of surgeon volume in radical prostatectomy outcomes. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] T. McCalmont,et al. Mycosis fungoides: the great imitator. , 2002, Journal of the American Academy of Dermatology.
[17] C. Begg,et al. The influence of hospital volume on survival after resection for lung cancer. , 2001, The New England journal of medicine.
[18] U. Hipler,et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. , 2001, Journal of the American Academy of Dermatology.
[19] A. Varghese,et al. Clinical Characteristics and Outcome of Patients With Extracutaneous Mycosis Fungoides , 2001 .
[20] T. Petrella,et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. , 2000, Blood.
[21] R. Kurzrock,et al. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. , 1999, Journal of the American Academy of Dermatology.
[22] R. Kurzrock,et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. , 1998, Blood.
[23] E. Partridge,et al. The National Cancer Data Base: Ten years of growth and commitment , 1998, CA: a cancer journal for clinicians.
[24] L. Wilson,et al. Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy , 1996, Cancer.
[25] L. Wilson,et al. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. , 1995, Archives of dermatology.
[26] C. Gisselbrecht,et al. Mycosis fungoides and the Sézary syndrome. , 1993, Nouvelle revue francaise d'hematologie.
[27] E. Vonderheid,et al. Infections complicating mycosis fungoides and Sézary syndrome. , 1992, JAMA.
[28] Z. Fuks,et al. Total-skin electron treatment of mycosis fungoides. , 1971, Radiology.
[29] B. Thiers. Folliculotropic Mycosis Fungoides: An Aggressive Variant of Cutaneous T-Cell Lymphoma , 2009 .
[30] C. Meijer,et al. Lymph node classification systems in cutaneous T‐cell lymphoma. Evidence for the utility of the working formulation of non‐Hodgkin's lymphomas for clinical usage , 1994, Cancer.